NanoViricides Appoints Baylor Professor Dr. Milton Boniuk as an Independent Board Member
WEST HAVEN, CONNECTICUT -- May 21, 2013 -- NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has appointed Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, as an independent member of the Company’s Board of Directors.
Dr. Boniuk is an astute and highly successful businessman and entrepreneur, in addition to being an accomplished eye surgeon, educator, and administrator. Currently, he is the Caroline F. Elles Chair Professor of Ophthalmology in the Alkek Eye Center at the Baylor College of Medicine, Houston, TX. He conducts a busy clinical practice in orbital surgery, eyelid reconstruction, ocular oncology and comprehensive ophthalmology. Additionally, he plays a major role in Baylor’s resident and fellow medical doctor education programs.
Dr. Boniuk has been a long term investor and strong supporter of NanoViricides, Inc.
“Milton’s strong business acumen, integrity, and professional expertise will be of great help in strengthening our corporate governance as well as fostering our drug development activities,” said Eugene Seymour, MD, MPH, CEO of the Company.
Dr. Boniuk has made significant contributions in cataract surgery, glaucoma, corneal dystrophies, retinal diseases and surgery. He is a nationally and internationally recognized expert in the pathology and surgical management of orbital and intra-ocular tumors. His description of the ocular pathology of the congenital rubella syndrome in 1967 was a landmark publication. Of note, Dr. Boniuk has made substantial medical contributions in areas that are of great significance to the Company, such as ocular adenoviral infections, that cause epidemic kerato-conjunctivitis (EKC). The Company has developed a drug candidate for EKC infection that was successfully tested in rabbits. These animals serve as a surrogate for the viral disease in human eyes.
“Dr. Boniuk brings a unique set of skills to the Board of NanoViricides, Inc.,” said Anil R. Diwan, PhD, President of the Company, adding, “He shares our enthusiasm for the novel biomimetic nanoviricides® technologies and the resulting anti-viral drugs. In addition to strengthening our corporate governance, he will be of great value in progressing our drug development programs into the clinic.”
Dr. Boniuk is also well known for his philanthropic endeavors. He and his wife Laurie founded the National Society for Parent and Child Development in 1989. In 1994, he established the Lions Eye Bank Foundation’s Milton Boniuk, M.D., Endowment Fund to support resident research in the Ophthalmology Department at Baylor. In 2004, Milton and Laurie Boniuk contributed $5 million to Rice University to establish the Boniuk Center for the Study and Advancement of Religious Tolerance. In 2013, they gave an additional $28.5M to Rice University to upgrade this Center to The Boniuk Institute for the Study and Advancement of Religious Tolerance. The Boniuk Institute will conduct research, public outreach and educational programming. Its mission is to foster multidisciplinary research that leads to innovative ways to understand and achieve religious tolerance.
Dr. Boniuk earned his MD at the Dalhousie University, Halifax, Nova Scotia, Canada, followed by an internship at the Victoria General Hospital, Halifax, Nova Scotia, Canada, and Residency at the Center for Ophthalmology, Jefferson Medical College - Wills Eye Hospital, Philadelphia, PA. In addition, he served a Fellowship in Ophthalmic Pathology at the world-renowned Armed Forces Institute of Pathology, Washington, DC. . . .
Those that proposed that the Doctor's recent purchase of 50,000 shares stood as a symbol of his confidence in the company now need to consider what his sale of a multiple of that amount might mean. Seriously, I think his recent purchase was meant to mitigate against any questions that these sales might raise. ~ loanranger (2014)
While doing a patent search in recent past, you said,...
All three of the above patents were granted during the last 9 months and assigned to Kineta, Inc. (Seattle, WA). Is Nanoviricide's FluCide™ the Binding Site Mimetic referred to in those patents or are they referring to some other FluCide ~ loanranger
My reply to you was that, in my view, it referred to FluCide(TM).
From the Kineta, Inc. webpage: Formula For Our Success
Kineta's area of specialization is translational drug development. We have refined a process of selecting high caliber early stage drug programs and efficiently advancing them into phase 1 human clinical trials.
All of Kineta’s drug programs are designed to reach valuable inflection points within three to five years, at which point they are made available for license to the larger pharmaceutical and biotechnology industry. The intellectual property associated with each program is held in a limited liability corporation (LLC) protecting investor value, simplifying transactions and maintaining the stability of our parent company. We believe our business model provides tremendous opportunity for the advancement of our drug programs and for strong and early returns to our investors.
Kineta is a privately held corporation that seeks aligned stakeholders who share our vision of improving human health through the development of breakthrough medicines. We encourage interested parties to learn more about Kineta. For additional information contact our Corporate Development team by sending us a message or by calling 206-378-0400 www.kinetabio.com/investors.html
Kineta, Inc. is a Seattle-based privately held Biotechnology Company specializing in clinical advancement of novel drug candidates derived from leading edge scientific research. Our world-class scientists are pioneers in developing life-changing classes of new drugs designed to be more effective and safer than current medicines. Kineta seeks to improve the lives of millions of people suffering from autoimmune and viral diseases and from severe pain. Our progressive business model focuses on targeting unmet medical needs and rapid achievement of important clinical milestones.
Read more:...fundamental vision of translational medicine, which is to efficiently and effectively translate basic scientific findings relevant to human disease into knowledge that benefits patients --- ebooks.cambridge.org/chapter.jsf?bid=CBO9780511976087&cid=CBO9780511976087A010
Have you found anything about the relationship between FluCide(TM) patent(s) and Kineta, Inc.? You were the one questioning, were you not? I am sure NNVC posters would be interested in the answer to your question.
NanoViricides, Inc. (2015) is advancing the FluCide(TM) candidate.
"There are many reasons an insider will sell a stock, but only one reason why insiders buy: They think the stock is undervalued and will eventually go up." ~ Peter Lynch
About commissioning and validation of the new, state of the art, Pilot Plant in Shelton, CT:
Jan. 7, 2015...All of the infrastructure systems needed for production of the nanoviricides® drug candidates are now operational at the new facility, and have either been validated by outside experts, or are in the process of such validation.
April 27, 2015...In another news, the Company reports that the process of commissioning of its new facility in Shelton is on course. Our Bio-Analysis Group has already moved operations to the new facility. Large Scale Chemistry Group is completing the necessary modifications to the facility to enable large scale production processes. Various laboratory instruments are being installed by vendors under warranty programs for installation qualification and operational qualification.
Commissioning and validation of a new pharmaceutical facility should be considered the optimal goal, as the ROI is not realized until the facility can make product. Budgets and timelines usually become the target focus through a majority of traditional construction projects, sometimes leaving the commissioning and validation of the facility as the final area of focus [3]. www.pharmamanufacturing.com/articles/2004/41/
It is important to note:
1) NanoViricides, Inc. commissioned the new state-of-the-art multi-kilogram Pilot Plant in Shelton, CT, to produce FluCide(TM)/GLP, sometime in Jan 2015 2) On Mar 31, 2015 - We are now progressing to a 1kg scale-up of FluCide(TM), and enabling in-process control instrumentation--- CMC studies to enable further scale-up from the current multi-100g scale of production to kg-scale production. CMC stands for "Chemistry, Manufacture, and Controls," and relates to being able to make the drug substance and the drug product in a reproducible fashion, batch after batch.
-We are now making the FluCide(TM) material for third and final/Phase III of Safety/Toxicology Studies in large animals!
June 1, 2015, 9:47 PM
FluCide
Phase I and II of tox successfully completed
Making material for last Phase in large animals
...
Eugene Seymour MD MPH Chief Executive Officer NanoViricides, Inc eugene@nanoviricides.com www.nanoviricides.com 310-486-5677 "NNVC" on the New York Stock Exchange
=============================================
About an excerpt from one of Patrick Cox's letter and NanoViricides, Inc....
The more transformational a technology is, the easier it is to get people doubting it. Take, for example, NanoViricides (OTCBB: NNVC). This company's remarkable technology combines nano-sized polymer structures with biological ligands -- nanoviricides. The ligands "signal" to the target viruses that they are inside human cells. The viruses attack these nanoviricides and are, in turn, dismantled and harmlessly removed.
I know this sounds like science fiction.
In fact, the company has proven the technology over and over in conjunction with some of the world's most important scientists. It's real. It works, and it will revolutionize the way medical science deals with a broad range of viruses. Viruses, incidentally, are only now beginning to be truly understood. It appears, in fact, that they play roles in conditions we never suspected, ranging from obesity to chronic fatigue syndrome. So NanoViricides' future is vast.
Nevertheless, there is a minor industry based on convincing investors that NanoViricides is some sort of hoax. For a long time, if you did a Google search on the company name, the top paid search results were screaming claims that the company was a scam. If you searched my name, it often returned accusation that I was part of the NanoViricides scam.
I wish, by the way, that I did own part of NanoViricides. I am prohibited by my arrangement with Agora Financial.
Dr. Eugene Seymour told me that he had tried to contact Google about putting an end to this slander, but could never get a response. Google's informal corporate slogan, by the way, is "Don't be evil."
Anyway, there are several reasons that people might attack a company in this manner. Some are probably simply trying to sell a report about NanoViricides, or at least get credit card information from people foolish enough to fall for the trick.
Sometimes, however, these tactics are part of a broader short attack. Many of you know, in fact, that these short attacks are taking place because you have been offered money to "rent" your shares. I hear about it constantly, and this does not happen to just NanoViricides. The last time I reported it, Pro-Pharmaceuticals was being targeted.
In general, the greater the company's potential, the more attractive it is to short attackers. If a company has generated a lot of "buzz," it is likely that a lot of "traders" have decided to buy shares. These people often know nothing about the company's management, technology or market potential. They're just surfing trends.
As a result, groups that specialize in short attacks can manipulate them. These groups are expert at spreading rumors. They seem to have people planted on the boards who can say just the right thing at just the right time to trigger a stampede.
When I lived in Silicon Valley, I knew quite well the man who was then Steve Jobs' CFO. He frequently described his job in terms of warfare. I was skeptical at first, but he convinced me that a group of people were waging war against him and his company. If he didn't fight back, they would succeed.
Why would anybody attack a company run by Steve Jobs? They did so because sophisticated traders, as you know, can make money by driving a stock price down. In the age of the Internet, with the means to reach millions of investors, this has become a serious problem. Normally, I try to ignore these attacks because they usually don't hurt the companies they attack. They hurt the investors who sell their stock at low prices. ~ Patrick Cox, Jan 11, 2011
Excerpt from NanoViricides, Inc, CEO letter to shareholders (2014)
Recent “Bear” Attack
As many of you know, a malicious and possibly criminal attack on our common stock was carried out on February 11, 2014, through the publication of a false and misleading article on Seeking Alpha. The intent of the article was to dramatically drive down our stock price. The article resulted in a highly increased daily trading volume of eight million shares, approximately 20 times our daily average. The information we have gathered suggests that this was an organized attack using false and inaccurate information designed to benefit short sellers in the stock. We have reported this conduct to the regulatory authorities and have retained legal counsel to investigate both the website that hosted this article and the anonymous blogger who authored it.
